A Novel Arenaviral Immunotherapy for Targeting Multiple Mutated KRAS Epitopes

Time: 1:30 pm
day: Day One Track C

Details:

  • Introduction to HOOKIPAs Platform for induction of tumor specific CD8+ T-cell responses
  • Overview on key clinical data demonstrating induction of unprecedented tumor specific CD8+ responses in humans
  • Overview and preclinical validation of HOOKIPA’s HB700 program targeting most frequent KRas mutations in pancreatic cancer, colorectal cancer and lung adenocarcinoma

Speakers: